Assessing clinical evidence regulatory requirements across Asia Pacific, Europe, and North America

Digital health product commercial strategies should not be constrained to a single market in this economy. Global go-to market strategies are necessary for companies to benefit from expanded market reach, patient impact, competitive advantage, fostered innovation and knowledge, and improved financial performance.

International Regulatory Pathways builds on the success of the Digital Health US Regulatory Pathways work to contemplate the global market by combining the expertise of global leaders from across the digital health product industry to foster innovation, drive progress, and harmonize regulatory efforts across Asia Pacific, Europe, and North America. This global project team brings diverse backgrounds and perspectives, essential for harmonizing the field.

Stay up to date on DiMe’s regulatory work

The project team will…

Conduct thorough evaluations of the regulatory landscapes and clinical evidence requirements in key global markets and identify obstacles and opportunities

Analyze and compare global regulations pertaining to digital health products, offering valuable insights to product developers to include their evidence generation and global go-to market strategy

Propel digital health products to reshape the global healthcare industry by outlining how to navigate complex international regulations to enable compliance and success on a global scale

Actively engage with regulatory authorities to accelerate time to market and decrease evidence collection and global go-to market costs

Project Partners

DiMe’s new global project, International Regulatory Pathways, builds upon the success of the Digital Health US Regulatory Pathways project by combining the expertise of global leaders from across the digital health product (DHP) industry to foster innovation, drive progress, and harmonize regulatory efforts.